Vistagen Therapeutics (VTGN) Equity Average (2017 - 2025)
Historic Equity Average for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $58.6 million.
- Vistagen Therapeutics' Equity Average fell 3264.69% to $58.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.6 million, marking a year-over-year decrease of 3264.69%. This contributed to the annual value of $92.3 million for FY2025, which is 4614.37% up from last year.
- Per Vistagen Therapeutics' latest filing, its Equity Average stood at $58.6 million for Q4 2025, which was down 3264.69% from $61.6 million recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' Equity Average ranged from a high of $118.8 million in Q1 2024 and a low of $9.5 million during Q2 2023
- For the 5-year period, Vistagen Therapeutics' Equity Average averaged around $66.8 million, with its median value being $74.1 million (2022).
- As far as peak fluctuations go, Vistagen Therapeutics' Equity Average surged by 1207008.85% in 2021, and later crashed by 8291.1% in 2023.
- Vistagen Therapeutics' Equity Average (Quarter) stood at $80.3 million in 2021, then plummeted by 68.7% to $25.1 million in 2022, then surged by 216.09% to $79.5 million in 2023, then grew by 9.54% to $87.0 million in 2024, then crashed by 32.65% to $58.6 million in 2025.
- Its Equity Average stands at $58.6 million for Q4 2025, versus $61.6 million for Q3 2025 and $63.6 million for Q2 2025.